Chinese herbal formulas for Hashimoto’s thyroiditis based on the thyroid-gut axis: multitarget synergistic mechanisms and boundaries of evidence - Report - MDSpire
Advertisement
Chinese herbal formulas for Hashimoto’s thyroiditis based on the thyroid-gut axis: multitarget synergistic mechanisms and boundaries of evidence
Clinical Report: Herbal Treatments from China for Hashimoto’s Thyroiditis
Overview
This review explores the potential of Chinese herbal formulas in managing Hashimoto’s thyroiditis (HT) through the thyroid-gut axis. It highlights the need for further clinical trials to establish the efficacy and safety of these treatments.
Background
Hashimoto’s thyroiditis is a prevalent autoimmune disorder that leads to hypothyroidism, primarily managed with levothyroxine therapy. However, this treatment does not address the underlying autoimmune mechanisms. Understanding the thyroid-gut axis offers insights into potential therapeutic interventions that could modify the disease process.
Data Highlights
The review included eight studies on Chinese herbal formulas targeting four pathological nodes: intestinal barrier repair, gut microbiota remodeling, immune homeostasis reconstruction, and endocrine function restoration.
Key Findings
Chinese herbal formulas may influence HT pathology through multitarget regulation of the thyroid-gut axis.
The proposed four-level linkage model integrates evidence from various studies on HT and gut health.
Current evidence is primarily derived from preclinical animal studies, indicating a need for more rigorous clinical trials.
Target combinations observed include intestinal barrier repair with immune homeostasis and gut microbiota remodeling.
Future research should focus on randomized controlled trials and standardized outcome assessments.
Clinical Implications
Clinicians should be aware of the potential role of the thyroid-gut axis in HT and consider the implications of gut health in managing this condition. However, reliance on herbal treatments should be approached cautiously until more robust clinical evidence is available.
Conclusion
Reiterate the need for randomized controlled trials and specific safety evaluations.
